Login to Your Account



Financings Roundup

Karyopharm Gets Mighty 'SINE' $19M B1 Round

By Marie Powers
Staff Writer

Friday, August 2, 2013
Karyopharm Therapeutics Inc. added to its impressive Series B commitment with a $19 million extension led by new investor Foresite Capital Management, with additional participation by New Leaf Venture Partners and an unnamed top-tier institutional investor and by current investor Delphi Ventures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription